Evidence map›Paper›PMID 35530353›Full record

ArticleFrontiers in oncology2022

Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study.

Shuping Qu, Xiaobing Zhang, Yutian Wu, Yan Meng, Hongyu Pan, Qiang Fang, Lei Hu, Jin Zhang, Ruoyu Wang, Lixin Wei and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 5 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. PD1Cancer immunology, immunotherapy : CII · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shuping QuDepartment of Hepatic Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Xiaobing ZhangDepartment of Hepatic Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Yutian WuDepartment of Hepatic Surgery, The First Hospital of Putian, Putian, China.
Yan MengTumor Immunology and Gene Therapy Center, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Hongyu PanDepartment of Hepatic Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Qiang FangDepartment of Hepatic Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Lei HuDepartment of Hepatic Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Jin ZhangDepartment of Hepatic Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Ruoyu WangDepartment of Hepatic Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Lixin WeiTumor Immunology and Gene Therapy Center, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Dong WuDepartment of Hepatic Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Second Military Medical University · CNPutian University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To compare the efficacy and safety of the combination of transcatheter arterial chemoembolization (TACE), Lenvatinib, and programmed cell death protein-1 (PD-1) inhibitors (combination group) with TACE (TACE group) in the treatment of patients with unresectable hepatocellular carcinoma (uHCC). Methods: We consecutively enrolled 110 patients with uHCC in this prospective cohort study, with 56 patients receiving combination treatment and 54 patients receiving TACE from November 2017 to September 2020. The differences in tumor response, survival benefit, and adverse events (AEs) were compared between the two groups. Factors affecting survival were identified Results: Compared with the TACE group, the combination group had a higher objective response rate (ORR) (67.9% vs. 29.6%, p < 0.001), longer median progression-free survival (mPFS) (11.9 vs. 6.9 months, P = 0.003) and overall survival (mOS) (23.9 vs. 15.3 months, p < 0.001). Multivariate analysis showed that the neutrophil-to-lymphocyte ratio (NLR) and the treatment option were independent factors associated with the PFS and OS. Further subgroup analysis showed that patients with low NLR (≤median 3.11) receiving combination therapy had better mPFS (20.1 vs. 6.2 months, P < 0.001) and mOS (28.9 vs. 15.2 months, P < 0.001) than those receiving TACE, while no obvious difference in PFS or OS was observed between the two groups in patients with high NLR (> 3.11). There were no unexpected toxicities in the combination group. Conclusion: Compared with TACE, the combination treatment demonstrated an improved clinical efficacy and manageable safety profile in patients with uHCC. Combination treatment showed better therapeutic efficacy in patients with low NLR; therefore, this ratio could be used to identify patients who will benefit from this treatment.

Indexed as

hepatocellular carcinomalenvatinibneutrophil-to-lymphocyte ratioprogrammed cell death-1 inhibitortranscatheter arterial chemoembolization

Identifiers

PMID35530353
PMCPMC9068979
OpenAlexW4224250169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.